Expression Patterns of Microenvironmental Factors and Tenascin-C at the Invasive Front of Stage II And III Colorectal Cancer: Novel Tumor Prognostic Markers

Mai Hashimoto
Iwate Medical University: Iwate Ika Daigaku

Noriyuki Uesugi
Iwate Medical University: Iwate Ika Daigaku

Mitsumasa Osaka
Iwate Medical University: Iwate Ika Daigaku

Naoki Yanagawa
Iwate Medical University: Iwate Ika Daigaku

Koki Otsuka
Iwate Medical University: Iwate Ika Daigaku

Yoshiki Kajiwara
National Defense Medical College: Boei Ika Daigakko

Hedeki Ueno
National Defense Medical College: Boei Ika Daigakko

Akira Sasaki
Iwate Medical University: Iwate Ika Daigaku

Tamotsu Sugai (tsugai@iwate-med.ac.jp)
Iwate Medical University: Iwate Ika Daigaku

Research

Keywords: colorectal cancer, cancer-associated fibroblasts, microenvironmental, Immunohistochemical

DOI: https://doi.org/10.21203/rs.3.rs-330480/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background.** Biological markers expressed in cancer cells and the surrounding cancer-associated fibroblasts (CAF) can be used for prediction of patient prognosis in colorectal cancer (CRC). Here, we used immunohistochemical techniques to evaluate cancer cells’ expression of specific biomarkers that are closely associated with neoplastic progression.

**Patients and Methods.** Immunohistochemical markers included Ki-67, p53, β-catenin, MMP7, E-cadherin and HIF1-α. We also characterized microenvironmental markers expressed by CAF, including expression of α-smooth muscle actin, CD10, podoplanin, fibroblast specific protein 1, platelet derived growth factor β, fibroblast association protein, tenascin-C (TNC), ZEB1 and TWIST1. The study population consisted of 286 CRC patients with stage II and III disease. Stage II and III CRC were divided into a first and a second cohort (for validation). The CRCs were stratified using cluster analysis. To identify the utility of prognostic markers in stage II and III CRC, univariate and multivariate analyses were performed in both cohorts.

**Results.** Stage II and III CRCs were stratified into 3 subgroups. Specific subgroups were significantly correlated to disease-free survival using univariate and multivariate analyses in the first cohort. High expression of TNC was identified as a single prognostic marker in both cohorts by univariate and multivariate analyses.

**Conclusions.** We suggest that the presence of a specific subgroup defined by multiple markers can be used for prediction of CRC outcome in stages II and III. In addition, we showed that high expression of TNC was correlated with a poorer prognosis in stages II and III of CRC.

Introduction

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women in the United States [1]. These trends for incidence and mortality are common worldwide [1]. Remarkable progress has been made in the diagnosis and treatment of CRC. In spite of such advances, CRC is often discovered at an advanced stage at which point achieving a cure is very difficult [2]. Therefore, the development of effective markers to predict patient prognosis of CRC is greatly needed.

The outcome of patients with CRC can be predicted by prognostic factors, such as the TNM staging system proposed by the UICC and AJCC [3, 4]. Additionally, novel and promising prognostic biomarkers are listed in the WHO classification 2019 [5]. There are 2 histological processes that are present within the tumor microenvironment at the invasive front of CRC: tumor budding and the desmoplastic reaction (DR) [6–9]. Tumor budding is defined as single cells or clusters of up to four tumor cells at the invasion front of CRC [6–8]. It is closely associated with both local and distant metastases and is therefore a histological biomarker of tumor progression and a poor prognosis [6–8]. The classification of the DR was recently proposed by Ueno et al. as a prognostic histological marker [9]. A pronounced desmoplastic stromal reaction in the microenvironment involves complex cellular interactions at the invasive front [10]. This theory posits that cooperation between cancer cells and cancer associated fibroblasts (CAFs) present within the tumor microenvironment is necessary to support tumor growth and progression [10, 11]. In addition, the microenvironment itself plays an important role in neoplastic progression and metastasis in CRC [10, 11]. Whereas such histological findings are widely used as markers for establishing a patient’s prognosis, they do not explain the underlying cellular processes that promote tumor growth and metastasis [12, 13]. Therefore, the discovery of additional markers would be very beneficial. We propose that identification of protein expression patterns in cancer cells and CAFs could provide new biological insights and guide the development of new therapies for CRC [12, 13].

In this study, we analyzed immunohistochemical data to identify possible protein expression patterns in stages II and III of CRC that predict patient outcome. We focused on markers that are closely associated with tumor growth and progression within the microenvironment.

Materials And Methods

**Patients**

CRC patients who underwent curative surgery at stages II or III at Iwate Medical University Hospital from January 2009 to December 2015 were included in the present study. A total of 286 patients included a first cohort (148 cases) and a second cohort for validation (138 cases). We used block randomization method in research design used to select and divide participants into different groups or conditions in order to avoid bias in the selection of two cohorts. Paraffin embedded tissues were well preserved, medical records were complete and patient status had been followed up, including overall survival and disease-free survival data that were confirmed through telephone interviews and by the mail. In addition, cases with invasion beyond the proper muscular layer were included for determination of the desmoplastic reaction [9]. Finally, patients who underwent preoperative chemoradiotherapy and emergency surgery were excluded. In addition, patients who had evidence of hereditary non-polyposis colorectal cancer or familial adenomatous polyposis were not included. The clinicopathological variables characterizing the patients included tumor location, stage and t stage, histological type, lymphatic/venous invasion and tumor budding. The variables were recorded according to the General Rules for Management of the Japanese Colorectal Cancer Association (Table 1) [14]. In addition, DR classification was determined based on Ueno's classification [9].

This study was approved by the local ethics committee of Iwate Medical University (approval number MH2020-070), and all patients provided informed consent.

**Determination of disease-free survival**
We determined the duration of disease-free survival at which metastasis was discovered during the follow-up period (2 times/year to 3 times/year) using computed tomography.

**Chemotherapeutic treatment after surgery for stage II or III CRC**

Following surgery, Capecitabine or UFT/UZEL (Tegafur Uracil + Calcium Folinate) were administered in stage II CRC (20/140 cases), whereas FOLFOX, including the drugs leucovorin calcium (folic acid), fluorouracil and oxaliplatin were used in stage III CRC (85/146 cases). The other 181 patients, including 120 cases in stage II and 61 cases in stage III did not receive additional chemotherapy following surgery.

**Tissue microarray construction (TMA)**

The TMAs were assembled using a manual tissue array (Azumaya Co, Tokyo, Japan). Five mm tissue cores were taken from each targeted lesion and placed into a recipient block containing 12 cores including 10 cancer tissues and 2 cores for control tissues (normal colon; CRC). After construction, 3-micron sections were cut and stained with hematoxylin and eosin on the initial slides to verify the histologic diagnosis. Serial sections were cut from the TMA block for immunohistochemical staining.

**Immunohistochemistry**

Microarray slides were incubated in 3% hydrogen peroxide to block endogenous peroxidase. Antigen retrieval was performed using an autoclave-based method, followed by incubation with the primary antibody overnight at 4°C in a high humidity cabinet. Slides were processed using the Dako Autostainer Universal Staining System (Dako, Glostrup, Denmark). Antibodies used in this study were classified into 2 subgroups: epithelial (cancer cells) and interstitial (cancer associated fibroblasts, CAF) markers. Antibodies targeting CAFs included the following: α-smooth muscle actin (α-SMA, Dako 1A4), CD10 (Dako, 56C6), podoplanin (Dako, D2-40), fibroblast specific protein 1 (FSP1; S100A4, Dako, polyclonal), platelet derived growth factor receptor (PDGFR-β; 28E1, Cell Signaling Technology), fibroblast association protein (FAP; Abcam, EPR20021) and tenascin-C (BBL, 4F10TT). For EMT, we utilized zinc finger E-box binding homeobox 1 (ZEB1, Sigma-Aldrich, polyclonal) and Twist-related protein 1 (TWIST1, Abcam, Twist2C1a). CAFs were recognized as “spindle-shaped cells” by experienced pathologists (T.S. and N.U.). Cytoplasmic staining of tumor cells was conducted with antibodies against α-SMA, CD10, podoplanin, FSP1, PDGFR-β, FAP and tenascin-C. Nuclear staining of fibroblasts was based on positivity for ZEB1 and TWIST1 expression. Furthermore, antibodies targeting cancer cells in this study included Ki-67 (Dako, MIB1) for proliferative activity, p53 (Dako, Do7) for p53 mutation, β-catenin (Dako, β-catenin-1) for activation of Wnt signaling, a central signal transducer in CRC, MMP7 (Daichi Fine Chemical, 141-7B2) for cancer progression, E-cadherin (Dako, NCH-38) for cellular adhesion and HIF1α (Novus Biologicals, polyclonal) for cancer-specific metabolic marker which may be associated with tumor progression. Detailed information of antibodies is summarized in supplementary Table 1.

**Assessment of scoring of immunohistochemical expression**

The expression of the markers was scored for both the intensity and extent of immunopositivity, as described in a previous report with slight modification [15]. The immunostaining intensity of the cancer cells and CAFs in the CRCs was classified into 4 categories as follows: negative, weak, moderate and strong. The immunostaining extent was semi-quantified as follows: 0%, 1-25%, 26-50%, 51-100%. The combination of intensity and extent was scored. Scores 2–3 were defined as a positive staining pattern, as shown in supplementary Table 2. In addition, the score was also sub-classified into low (score 0-1) and high expression (score 2-3). Assessment of scoring was performed by two pathologists. If agreement was not obtained between the pathologists, we asked an additional pathologist regarding the assessment. Finally, the score was determined by agreement of more than two pathologists.

In the present study, a wide range of expression levels was observed for all the markers. Thus, we selected the deepest invasive region as a target area to measure the expression levels of markers.

**Hierarchical analysis of the expression of CAF and EMT markers**

Hierarchical cluster analysis was performed for clustering of the samples according to the expression level in order to achieve maximal homogeneity for each group and the greatest differences between the groups using open-access clustering software (Cluster 3.0 software; bonsai.hgc.jp/~mdehoon/software/cluster/software.htm). The clustering algorithm was set to centroid linkage clustering, which is the standard hierarchical clustering method used in biological studies.

**Statistical analysis**

Data were analyzed using JMP Pro 13.0 software (SAS, Tokyo, Japan). Data obtained for clinicopathological features (sex, location, pT, stage, histological type, lymphatic invasion, venous invasion, tumor budding, desmoplastic reaction, overall survival, disease-free survival) and subgroup (subgroups 1, 2 and 3) were analyzed using Fisher’s exact test. In addition, the comparison of the age distributions within each subgroup was performed using the Kruskal-Wallis test. We used Fisher’s exact tests with a Bonferroni correction to compare the examined markers within each subgroup.

Kaplan–Meier analyses were performed using a log-rank test for survival analyses. Univariate and multivariate analyses were conducted with Cox proportional hazards model to identify statistical differences for prediction of lymph node metastasis. The level of significance was p< 0.05, and the confidence interval (CI) was determined at the 95% level.

**Results**
A representative figure is shown in Figure 1.

1. Analyses of clinicopathological variables and biological markers in the first cohort

1.1 Hierarchical clustering based on marker scores in first cohort

We performed hierarchical clustering based on marker scores to evaluate differences in expression patterns of cancer cell, CAF- and EMT-related markers in stage II and III CRC. Three distinct subgroups were stratified, as shown in Figure 2. The vertical line shows the expression of each marker in cancer cells and fibroblasts and the horizontal lines denote “relatedness” between samples. There was no statistical difference in the frequency of clinicopathological variables among subgroups 1, 2 and 3. Although immature desmoplastic reaction present in subgroup 1 showed a high frequency among the 3 subgroups, such association between the 3 subgroups did not quite reach a statistically significant level ($p = 0.0508$). However, the frequency of disease-free survival was significantly higher in subgroup 1 than in subgroup 2 ($p<0.0001$). Detailed data are shown in Table 2.

1.2. Survival analyses of each subgroup in the first cohort

Kaplan–Meier analyses were performed to determine the association between the disease-free survival frequencies and the subgroups. Subgroup 1 had a poorer disease-free survival, compared to subgroup 2 ($p < 0.0001$). However, overall survival did not differ among the subgroups (supplementary Figure 1).

1.3. The association of clinicopathological variables and subgroups with survival of stage II and III CRC patients: univariate and multivariate analyses of the first cohort (a stepwise logistic regression analysis)

The univariate analysis of stage II and III CRC patients (Table 3-a) identified 5 factors: histologic type (mucinous carcinoma vs. well differentiated adenocarcinoma), stage (II vs III), desmoplastic reaction (mature vs immature) and subgroup (1 vs 2; 1 vs 3). Table 3-b reveals that 3 factors (mucinous carcinoma vs well differentiated adenocarcinoma, mature DR versus immature DR, subgroup 1 versus 2) were retained in the multivariate logistic regression analysis.

Using a similar method, we performed univariate analysis for screening of overall survival of stage II and III CRC patients. As a result, 3 factors, including stage (II vs III), desmoplastic reaction (mature vs immature), and subgroup (1 vs 2) were identified in univariate analysis (Table 3-c). However, no factors were retained in multivariate analysis (Table 3-d).

1.4. Association of individual markers with individual subgroups in the first cohort

The frequency of positive scores (score 2 or 3) of SMA was higher in subgroup 2 than in subgroup 1. There were statistically significant differences in the frequencies of positive scores among subgroups 1, 2 and 3 (subgroup 1, 2 > 3). In addition, significant differences in the frequencies of positive scores for tenascin-C between subgroups 1 and 2, and 3 were found (subgroup 1 > 2, 3). The frequency of the positive score for ZEB1 was statistically higher in subgroup 2 than in subgroup 3. Next, there was a statistically significant difference in the frequencies of positive scores for TWIST1 between subgroup 3 and subgroup 1 (subgroup 1 > 3). The positive score for p53 was significantly greater in subgroup 2 than in subgroups 1 and 3. Furthermore, there was a significant difference in the frequencies of positive scores for p53 between subgroups 1 and 3. Finally, we observed statistically significant differences in the frequencies of positive MMP7 scores among subgroups 1, 2 and 3 (subgroup 1, 2 > 3). Detailed data are shown in Figure 3.

1.5. The association of clinicopathological variables and individual markers with the survival of stage II and III CRC patients: univariate and multivariate analyses of the first cohort

With regard to disease-free survival, 3 variables (stage II vs III; mature vs immature; mucinous carcinoma vs well differentiated adenocarcinoma) and one marker (tenascin-C) were identified in univariate analysis (Table 4-a). Among those 4 parameters, 2 variables, including desmoplastic reaction and histological type and one marker, tenascin-C, were retained in multivariate analysis (Table 4-b). In overall survival, stages (II vs III) and desmoplastic reaction (mature vs immature) were identified in multivariate analysis (Table 4-c). Desmoplastic reaction (mature vs immature) was retained in multivariate analysis (Table 4-d).

2. Analyses of clinicopathological variables and individual markers in the second cohort (validation)

2.1. The association of clinicopathological variables and individual markers with the survival of stage II and III CRC patients: univariate and multivariate analyses of the second cohort

With regard to disease-free survival, 5 variables (pT3 vs. pT4; stage II vs. III; positive venous invasion vs. negative venous invasion; low grade budding vs. high grade budding; mature vs. immature) and 2 markers (tenascin-C and β-catenin) were identified in univariate analysis (Table 5-a). However, only 1 factor (tenascin-C) was retained in multivariate analysis (Table 5-b). In overall survival, 4 variables (pT3 vs. pT4; stage II vs. III and desmoplastic reactions (mature vs. immature; and intermediate vs. mature) and 2 individual markers (tenascin-C and Ki-67) were detected in univariate analysis (Table 5-c). Only the positive expression of tenascin-C was retained in multivariate analysis (Table 5-d).

Discussion

Certain proteins expressed by microenvironmental cells play crucial roles in neoplastic progression of CRC. Those proteins may be derived from cancer cells or from stromal cells (sometimes termed “cancer-associated fibroblasts” (CAFs) [12, 13]. Proteins expressed by cancer cells and CAFs interact with one
another and this interaction is likely important at the invasive front [12, 13]. According to that theory, the combination of proteins from cancer cells and CAFs mediate tumor growth and progression [12, 13]. In the present study, specific expression patterns could be correlated with the prognosis of stage II and III CRC patients. Therefore, the current results suggest that a specific subgroup (identified here by stratification) can be used to evaluate the role and significance of various proteins produced by microenvironmental cells. Finally, in the present study, subgroup 1 was correlated with disease-free survival. However, the presence in subgroup 1 did not correlate with overall survival. The reason remains unknown.

Tenascin-C (TNC) is an extracellular matrix molecule that drives the progression of many types of human cancer. The basis for its actions remains unclear [16]. TNC is associated with organogenesis accompanying cell proliferation and migration, resulting in the epithelial-mesenchymal transition (EMT) that might result from interactions between cancer cells and stromal cells [17]. EMT is the process by which polarized epithelial cells are converted into mesenchymal cells during cancer progression. As a result, carcinoma cells lose their epithelial polarity and intercellular connections, allowing them to escape the surrounding epithelium [17, 18]. The expression of TNC facilitates such phenotypic changes, alterations that are enhanced by TGF-β, a promoter of EMT [16–18]. Murakami et al. revealed that TNC in primary CRC stroma might be a novel biomarker that is predictive of postoperative prognosis [18]. Finally, TNC may promote EMT-like change and proliferation, alterations that lead to poor prognosis in CRC patients [17].

TNC may be involved in cancer growth and metastatic processes via the Hedgehog (HH) signaling pathway, caused either by mutations in the pathway (ligand independent) or through HH overexpression (ligand dependent) [19]. HH signaling starts with secretion of the HH ligand, followed by secretion of Patched (PTC), the transmembrane protein Smoothened (SMO) and three GLI (Glioma-associated oncogene) zinc finger transcription factors [20]. The HH/GLI1 pathway promotes cancer growth, stem cell self-renewal and metastatic behavior in advanced CRC [21]. Human CRC stem cells require active HH/GLI1 signaling for survival and self-renewal [22]. Our finding suggests that activation of CAF at the invasive front is caused by high expression of TNC facilitated via HH signaling [23]. In addition, accumulating evidence suggests that activated HH signaling plays an important role in neoplastic transformation as well as the development of drug resistance of human cancers [24]. Thus, HH signaling during tumorigenesis and the development of chemo-resistance are closely associated. Those findings suggest that therapeutic strategies might target such signals in human cancers and their relapse [23, 24]. For example, cyclopamine is an HH signal pathway antagonist and consequently is expected to improve the survival of patients with CRC by inhibiting the proliferation of colon cancer cells [25]. Previous study showed that cyclopamine treatment results in decreased levels of mRNA coding for HH, SMO and PTCH, all of which were highly expressed in colon cancer cell lines [25]. These findings may influence potential therapeutic strategies because TNC expression by CAF may be targeted in future molecular therapies.

High expression of TNC was reported to be a prognostic marker for CRC through induction of EMT and cell proliferative activity [17]. According to that study, TNC may facilitate EMT-like changes and could be associated with a poor prognosis of CRC patients. This finding is consistent with other data showing that cancer cell-derived TNC promotes cancer cell invasion via EMT regulation. Thus, it is a novel indicator of poor prognosis [26]. In the present study, we found that even in stages II and III, intermediate stages that account for the majority of surgically resected CRC, TNC was an independent prognostic marker. This result was validated by analysis of a second cohort. The present results showed that TNC in primary CRC stroma has the potential to be a novel biomarker that predicts postoperative prognosis.

There are some limitations to this study. First, the immunohistochemical markers we used in the present study may not yield consistent results. For clinical application, immunohistochemical reagents must be reliable and reproducible. In that regard, many immunohistochemical markers that are closely associated with the formation of the microenvironment have been analyzed. Such immunohistochemical markers should yield reliable and reproducible results. We believe that the current study provides exactly those data. Second, heterogeneous expression of the markers examined in the present study may be a problematic issue in the determination of marker expression level. Although there may be no way to avoid this problem, we suggest that the invasive front of cancer cells, critical for tumor progression, is the best region to measure immunohistochemical expression levels of chosen markers [10, 11]. Finally, although there are many different reports regarding prognostic factors in CRC [27, 28], the different results may reflect the choice of markers, patient stage, heterogeneity of expression, staining platform, judging methods and cut-off value. In the present study, we suggest that the current results are reliable and reproducible under the conditions we employed.

In conclusion, cancer cells and CAFs express many proteins that modulate neoplastic progression and metastasis. In the present study, we found that specific expression patterns may allow the prediction of patient outcome in CRC. In addition, the expression of TNC by CAFs might be a potential prognostic biomarker in stage II and III CRC patients. These results highlight a potential role for TNC in CRC tumor progression and provide novel mechanistic insights into the roles of HH, as it is associated with high expression of TNC in driving CRC progression. Our findings also suggest that TNC could be a critical target gene for the treatment of CRC. However, further study will be needed in the near future to confirm these results.

**Abbreviations**
cancer associated fibroblast, CAF; colorectal cancer, CRC; tissue microarray, TMA; matrix metalloproteinase-7, MMP7; fibroblast specific protein 1, FSP1; platelet derived growth factor receptor beta, PDGFR-β; fibroblast associated protein, FAP; zinc finger E-box binding homeobox 1, ZEB1; twist-related protein 1, TWIST1

**Declarations**

**Acknowledgment**

We gratefully acknowledge the technical assistance of members of the Department of Molecular Diagnostic Pathology, Iwate Medical University for their support.
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author contributions

Mai Hashimoto, who is the first author, constructed the figures and tables and performed the statistical analyses. M Osakabe assisted statistical analyses. Y Kajiwara and H Ueno supported pathological interpretation of desmoplastic reactions. N Yanagawa, and N Uesugi helped in the interpretation of pathological findings. K Otsuka and A Sasaki provided clinical support during the preparation of the manuscript. T Sugai, who is the corresponding author, contributed to the preparation of the manuscript, including all aspects of the data collection and analysis.

Conflict of interest statement: We declare that we have no conflicts of interest.

Consent of publication:

Not applicable

Conflict of interest statement: We declare no conflicts of interest.

Funding

No funding was received for this study.

Ethical approval and consent to participate

Informed consent was obtained from each patient according to institutional guidelines, and the research protocols were approved by the ethics committee of Iwate Medical University Hospital (approval number MH2020-070).

Human rights statement and informed consent:

All procedures were performed in accordance with the ethical standards of the Iwate Medical University and with the Declaration of Helsinki. Substitute for informed consent (approval by the institutional review board of Iwate Medical University) was obtained from all patients included in the study.

References

1. Siegel RL, Miller KD, Goding Sauer A, Sauer A, Fedewa SA, Butterly LF, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–64. doi:10.3322/caac.21601.
2. Chen FW, Sundaram V, Chew TA, et al. Advanced-Stage Colorectal Cancer in Persons Younger Than 50 Years Not Associated With Longer Duration of Symptoms or Time to Diagnosis. Clin Gastroenterol Hepatol. 2017;15:728–37.e3. doi:10.1016/j.cgh.2016.10.038.
3. Moccia F, Tolone S, Allaria A, Napolitano V, Rosa D, Ilaria F, et al. Lymph Node Ratio Versus TNM System As Prognostic Factor in Colorectal Cancer Staging. a Single Center Experience. Open Med (Wars). 2019;14:523–31. doi:10.1515/med-2019-0058.
4. Pupp G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med. 2010;134:837–52. doi:10.1043/1543-2165-134.6.837.
5. Nagtegaal ID, Arends MJ, Salto-Tellez M. Colorectal adenocarcinoma. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2019. pp. 177–91.
6. Lugli A, Kirsch R, Ajikyo Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299–1311. doi: 10.1038/modpathol.2017.46.
7. Watanabe T, Muro K, Ajiko Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34. doi:10.1007/s10147-017-1101-6.
8. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25:1315–25. doi:10.1038/modpathol.2012.94.
9. Ueno H, Ishiguro M, Nakatani E, Ishikawa T, Uetake H, Murotani K, et al. Prognostic value of desmoplastic reaction characterization in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial). Br J Cancer. 2021. doi:10.1038/s41416-020-01222-8. Online ahead of print.
10. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding OncoTarget. 2010;1:651–61. doi:10.18632/oncotarget.199.
11. Tommelein J, Verset L, Boterberg T, Demetter P, Bracke M, De Wever O. Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol. 2015;5:63. doi:10.3389/fonc.2015.00063.
12. Sugai T, Yamada N, Eizuka M, Sugimoto R, Usugi N, Osakabe M, et al. Vascular Invasion and Stromal S100A4 Expression at the Invasive Front of Colorectal Cancer are Novel Determinants and Tumor Prognostic Markers. J Cancer. 2017;8:1552–61. doi:10.7150/jca.18685.
13. Sugai T, Usugi N, Kitada Y, Yamada N, Osakabe M, Eizuka M, et al. Analysis of the expression of cancer-associated fibroblast- and EMT-related proteins in submucosal invasive colorectal cancer. J Cancer. 2018;9:2702–12. doi:10.7150/jca.25646.
14. Hashiguchi Y, Muro K, Saito Y, Yamada N, Osakabe M, Eizuka M, et al. Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42. doi:10.1007/s10147-019-01485-z.

15. Sasaki K, Sugai T, Ishida K, Osakabe M, Amano H, Kimura H, et al. Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. Hum Pathol. 2018;79:1–8. doi:10.1016/j.humpath.2018.03.006.

16. Sun Z, Schwenzer A, Rupp T, Mardamoorthoo D, Vegliante R, Lefebvre O, et al. Tenascin-C Promotes Tumor Cell Migration and Metastasis through Integrin alpha9beta1-Mediated YAP Inhibition. Cancer Res. 2018;78:950–61. doi:10.1158/0008-5472.CAN-17-1597.

17. Yang Z, Zhang C, Qi W, Cui C, Cui Y, Xuan Y. Tenascin-C as a prognostic determinant of colorectal cancer through induction of epithelial-to-mesenchymal transition and proliferation. Exp Mol Pathol. 2018;105:216–22. doi:10.1016/j.yexmp.2018.08.009.

18. Murakami T, Kikuchi H, Ishimatsu H, Iino I, Hirotu A, Matsumoto T, et al. Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis. Br J Cancer. 2017;117:1360–70. doi:10.1038/bjc.2017.291.

19. Yang Z, Zhang C, Feng Y, Quan M, Cui Y, Xuan Y. Tenascin-C predicts poor outcomes for patients with colorectal cancer and drives cancer stemness via Hedgehog signaling pathway. Cancer Cell Int. 2020;20:122. doi:10.1186/s12935-020-01188-w.

20. Ruiz i Altaba A. Hedgehog signaling and the Gli code in stem cells, cancer, and metastases. Sci Signal. 2011;4: Pt9. doi:10.1126/scisignal.2002540.

21. Gulino A, Ferretti E, De Smaele E. Hedgehog signalling in colon cancer and stem cells. EMBO Mol Med. 2009;1:300–2. doi:10.1002/emmm.200900042.

22. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piquet V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/ AKT pathways. Proc Natl Acad Sci USA. 2007;104:5895–900. doi:10.1073/pnas.0700776104.

23. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244:143–63. doi:10.1016/j.canlet.2006.02.017.

24. Sari IN, Phi LTH, Jun N, et al. Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells. Cells. 2018;7:208. doi:10.3390/cells7110208.

25. Wu JY, Xu XF, Xu L, Niu PQ, Wang F, Hu GY, et al. Cyclopamine blocked the growth of colorectal cancer SW116 cells by modulating some target genes of Gli1 in vitro. Hepatogastroenterology. 2011;58:1511–8. doi:10.5754/hge10765.

26. Takahashi Y, Sawada G, Kuras hige J, Matsumura T, Uchi R, Ueo H, et al. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells. Anticancer Res. 2013;33:192.

27. Jang BG, Kim HS, Chang WY, Bae JM, Oh HJ, Wen X, et al. Prognostic significance of stromal GREM1 expression in colorectal cancer. Hum Pathol. 2017;62:56–65. doi:10.1016/j.humpath.2016.12.018.

28. Oh HJ, Bae JM, Wen XY, Cho NY, Kim JH, Kang GH. Overexpression of POSTN in Tumor Stroma Is a Poor Prognostic Indicator of Colorectal Cancer. J Pathol Transl Med. 2017;51:306–13. doi:10.4132/jptm.2017.01.19.

**Tables**

**Table 1. Clinicopathological findings in stage II and III colorectal cancer.**
| Variable                        | Cohort 1 (%) | Cohort 2 (%) | p value |
|--------------------------------|--------------|--------------|---------|
| Total                          | 148          | 138          |         |
| Age, median (range) (y)        | 67.5 (34-94) | 70.0 (41-88) | 0.1583  |
| Sex                            | Man          | 90 (60.8)    | 81 (58.7) | 0.7193 |
|                                | Woman        | 58 (39.2)    | 57 (41.3) |         |
| Location                       | Right colon  | 30 (20.3)    | 32 (23.2) | 0.4271 |
|                                | Left colon   | 64 (43.2)    | 49 (35.5) |         |
|                                | Rectum       | 54 (36.5)    | 57 (41.3) |         |
| pT                             | pT3          | 129 (86.5)   | 111 (80.4) | 0.1474 |
|                                | pT4          | 19 (13.5)    | 27 (19.6) |         |
| Stage                          | II           | 71 (48.0)    | 69 (50.0) | 0.8129 |
|                                | III          | 77 (52.0)    | 69 (50.0) |         |
| Histological type              | WDA          | 17 (11.5)    | 26 (18.8) | 0.0681 |
|                                | MDA          | 121 (81.8)   | 109 (79.9) |         |
|                                | PDA          | 2 (1.4)      | 1 (0.7)   |         |
|                                | PAP          | 6 (4.1)      | 1 (0.7)   |         |
|                                | MUC          | 2 (1.4)      | 1 (0.7)   |         |
| Lymphatic invasion             | Positive     | 130 (87.8)   | 129 (93.5) | 0.4404 |
|                                | Negative     | 18 (12.2)    | 9 (6.5)   |         |
| Venous invasion                | Positive     | 129 (87.2)   | 128 (92.8) | 0.4534 |
|                                | Negative     | 19 (12.8)    | 10 (7.2)  |         |
| Tumor budding                  | Low          | 117 (79.1)   | 108 (78.3) | 0.8861 |
|                                | High         | 31 (20.9)    | 30 (21.7) |         |
| Desmoplastic reaction          | Mature       | 65 (43.9)    | 61 (44.2) | 0.9877 |
|                                | Intermediate | 53 (35.8)    | 49 (35.5) |         |
|                                | Immature     | 30 (20.3)    | 28 (20.3) |         |
| Disease-free survival, median (range) (d) | 1857 (33-3196) | 1835 (93-3308) |         |
| Overall survival, median (range) (d) | 3077 (52-3196) | 2195 (93-3308) |         |

WDA, well-differentiated adenocarcinoma. MDA, moderately differentiated adenocarcinoma. PDA, poorly differentiated adenocarcinoma. PAP, papillary carcinoma. MUC, mucinous carcinoma.

Table 2. Clinicopathological variables according to each subgroup in the first cohort.
| Subgroup 1 (%) | Subgroup 2 (%) | Subgroup 3 (%) | p value |
|---------------|---------------|---------------|---------|
| Total         | 32            | 74            | 42      | 0.1971  |
| Age median (range) (y) | 69.0 (43-94) | 67.0 (34-92) | 67.5 (42-88) | 1.0000  |
| Sex           | Man           | Woman         | Right colon | 87.5 (21.9) | 15 (20.3) | 8 (19.0) | 0.9516  |
|               | Woman         | Right colon   | Left colon  | 67.0 (34-92) | 30 (40.5) | 19 (45.2) | 0.1971  |
| Location      | Right colon   | Left colon    | Rectum     | 10 (31.2) | 29 (39.2) | 15 (35.7) | 0.1971  |
| pT            | pT3           | pT4           | Stage      | II         | 13 (40.6) | 37 (50.0) | 21 (50.0) | 0.6456  |
|               |               |               | III        | 19 (59.4) | 37 (50.0) | 21 (50.0) | 0.6456  |
| Histological type | WDA          | MDA           | PDA        | 0 (0.0) | 0 (0.0) | 2 (4.8) | 0.1125  |
|               | MDA           | PDA           | PAP        | 3 (9.4) | 3 (4.1) | 0 (0.0) | 0.1125  |
| Lymphatic invasion | Positive     | Negative      | Venous invasion | 27 (84.4) | 65 (87.8) | 38 (90.5) | 0.7149  |
|               |               | Venous invasion | Positive | 29 (90.6) | 61 (82.4) | 39 (92.9) | 0.2694  |
| Tumor budding  | Low           | High          | Desmoplastic reaction | Mature | 8 (25.0) | 36 (48.6) | 21 (50.0) | 0.0508  |
|               |               | High          | Immature   | 11 (34.4) | 27 (36.5) | 15 (35.7) | 0.0508  |
|               |               |               | Intermediate | 28 (87.5) | 58 (78.4) | 31 (73.8) | 0.3738  |
| Disease-free survival | Positive     | Negative      | Overall survival | Positive | 10 (31.6) | 10 (13.5) | 7 (16.7) | 0.0999  |
|               |               | Overall survival | Alive     | 20 (62.5) | 64 (86.5) | 35 (83.3) | 0.0999  |

WDA, well-differentiated adenocarcinoma. MDA, moderately differentiated adenocarcinoma. PDA, poorly differentiated adenocarcinoma. PAP, papillary carcinoma. MUC, mucinous carcinoma. *, p<0.0001

Table 3. Association of clinicopathological variables and subgroups with disease-free survival and overall survival in the first cohort in univariate and multivariate analyses.
Table 4. Association of clinicopathological variables and individual marker with disease-free survival and overall survival in the first cohort in univariate and multivariate analyses.

| Variables                        | a. Univariate analysis | b. Multivariate analysis | c. Univariate analysis | d. Multivariate analysis |
|----------------------------------|------------------------|--------------------------|------------------------|--------------------------|
|                                  | HR 95%CI                | p value                  | HR 95%CI               | p value                  |
| Disease-free survival            |                        |                          |                        |                          |
| Sex                              | Woman vs man           | 1.420                    | 0.807-2.477            | 0.2207                   |
| Location                         | Rectum vs Left colon   | 1.488                    | 0.784-2.864            | 0.2238                   |
|                                  | Right colon vs Left colon | 1.671                  | 0.778-3.476            | 0.1821                   |
|                                  | Right colon vs Rectum  | 1.123                    | 0.534-2.260            | 0.7508                   |
| pT                               | pT4 vs pT3             | 1.488                    | 0.646-3.007            | 0.3261                   |
| Stage                            | III vs II              | 2.319                    | 1.299-4.322            | 0.0041                   |
| Histological type                | MUC vs WDA             | 10.443                   | 1.857-58.726           | 0.0253                   |
| Lymphatic invasion               | Positive vs Negative   | 2.444                    | 0.895-10.069           | 0.0865                   |
| Venous invasion                  | Positive vs Negative   | 1.473                    | 0.643-4.255            | 0.3878                   |
| Tumor budding                    | High vs Low            | 1.386                    | 0.707-2.548            | 0.3275                   |
| Desmoplastic reaction            | Immature vs Intermediate | 1.766                  | 0.894-3.446            | 0.1003                   |
|                                  | Immature vs Mature     | 3.023                    | 1.486-6.183            | 0.0025                   |
|                                  | Intermediate vs Mature | 1.711                    | 0.869-3.435            | 0.1200                   |
| Subgroup                         | Subgroup 1 vs 2        | 3.626                    | 1.860-7.224            | 0.0002                   |
|                                  | Subgroup 1 vs 3        | 2.024                    | 1.036-4.049            | 0.0392                   |
|                                  | Subgroup 3 vs 2        | 1.791                    | 0.868-3.697            | 0.1135                   |

WDA, well-differentiated adenocarcinoma. MUC, mucinous carcinoma. HR, hazard ratio. 95%CI, 95% confidence interval.
| Variables                                      | a. Univariate analysis | b. Multivariate analysis | c. Univariate analysis | d. Multivariate analysis |
|-----------------------------------------------|------------------------|--------------------------|------------------------|--------------------------|
|                                               | HR  | 95%CI          | p value                | HR  | 95%CI          | p value                | HR  | 95%CI          | p value                |
| Disease-free survival                         |     |                |                        |     |                |                        |     |                |                        |
| Stage                                         |     |                |                        |     |                |                        |     |                |                        |
| III vs II                                     | 2.319 | 1.299-4.322 | 0.0041                 | 1.760 | 0.943-3.430 | 0.0762                 | 2.575 | 1.139-6.570 | 0.0222                 |
| Histological type MUC vs WDA                  | 10.443 | 1.857-58.726 | 0.0253                 | 15.097 | 2.505-90.973 | 0.0132                 | 5.001 | 0.929-33.667 | 0.2451                 |
| Desmoplastic reaction Immature vs Mature      | 1.766 | 0.894-3.446 | 0.1003                 | 1.788 | 10.725-4.257 | 0.2004                 |     |                |                        |
| Histological type MUC vs WDA                  | 0.694 | 0.250-2.821 | 0.5468                 | 0.628 | 0.187-3.905  | 0.5532                 |     |                |                        |
| Histological type MUC vs WDA                  | 1.690 | 0.798-3.254 | 0.1606                 | 1.412 | 0.472-3.453  | 0.5025                 |     |                |                        |
| Histological type MUC vs WDA                  | 1.019 | 0.583-1.821 | 0.9477                 | 1.039 | 0.486-2.307  | 0.9215                 |     |                |                        |
| Histological type MUC vs WDA                  | 0.677 | 0.209-4.150 | 0.6111                 | 0.357 | 0.072-6.461  | 0.3876                 |     |                |                        |
| Histological type MUC vs WDA                  | 0.501 | 0.120-1.392 | 0.2067                 | 0.278 | 0.0154-1.334 | 0.127                  |     |                |                        |
| Histological type MUC vs WDA                  | 2.694 | 1.293-6.557 | 0.0065                 | 2.317 | 1.068-5.870  | 0.0324                 | 2.052 | 0.840-6.130  | 0.1201                 |
| Histological type MUC vs WDA                  | 0.988 | 0.550-1.863 | 0.9680                 | 0.764 | 0.351-1.786  | 0.5176                 |     |                |                        |
| Histological type MUC vs WDA                  | 1.269 | 0.584-3.325 | 0.5730                 | 2.094 | 0.623-13.018 | 0.2638                 |     |                |                        |
| Histological type MUC vs WDA                  | 1.512 | 0.851-2.639 | 0.1554                 | 1.185 | 0.533-2.540  | 0.6673                 |     |                |                        |
| Histological type MUC vs WDA                  | 1.139 | 0.653-2.011 | 0.6477                 | 1.245 | 0.579-2.736  | 0.5754                 |     |                |                        |
| Histological type MUC vs WDA                  | 0.629 | 0.359-1.098 | 0.1023                 | 0.504 | 0.231-1.077  | 0.0767                 |     |                |                        |
| Histological type MUC vs WDA                  | 1.621 | 0.890-3.069 | 0.1096                 | 1.205 | 0.560-2.734  | 0.6383                 |     |                |                        |
| Histological type MUC vs WDA                  | 0.770 | 0.401-1.395 | 0.3974                 | 0.979 | 0.419-2.127  | 0.9578                 |     |                |                        |
| Histological type MUC vs WDA                  | 0.461 | 0.101-8.172 | 0.4961                 | 0.297 | 0.062-5.344  | 0.3187                 |     |                |                        |
| Histological type MUC vs WDA                  |     |                |                        |     |                |                        |     |                |                        |

WDA, Well-differentiated adenocarcinoma. MUC, mucinous carcinoma. HR, Hazard ratio. 95%CI, 95%confidence interval. *, could not analyze, why all cases were positive expression of the marker.

Table 5. Association of clinicopathological variables and individual markers with disease-free survival and overall survival in the second cohort in univariate and multivariate analyses.
| Variables                      | a. Univariate analysis | b. Multivariate analysis | c. Univariate analysis | d. Multivariate analysis |
|-------------------------------|------------------------|--------------------------|------------------------|--------------------------|
|                               | HR 95%CI p value       | HR 95%CI p value         | HR 95%CI p value       | HR 95%CI p value         |
| Disease-free survival         |                        |                          |                        |                          |
| Sex                           | Woman vs Man 0.819 0.430-1.512 0.5283 | 0.919 0.395-2.048 0.8320 |
| Location                      | Right colon vs Left colon 1.982 0.976-4.345 0.0588 | 1.617 0.639-4.603 0.3180 |
| pT                            | pT4 vs pT3 2.279 1.142-4.307 0.0208 | 1.527 0.714-3.112 0.2662 | 2.630 1.065-5.986 0.0369 | 1.936 0.746-4.670 0.1667 |
| Stage                         | III vs II 3.114 1.633-6.334 0.0004 | 1.991 0.977-4.301 0.0581 | 4.599 1.847-13.885 0.0007 | 2.619 0.980-8.321 0.0552 |
| Histological type             | WDA vs MDA 0.627 0.264-1.492 0.2657 |                          | 0.787 0.269-2.303 0.6533 |
| Lymphatic invasion            | Positive vs Negative 4.334 0.944-76.833 0.0620 |                          | 2.447 0.516-43.777 0.3125 |
| Venous invasion               | Positive vs Negative 4.855 1.057-86.076 0.0401 | 4.073 0.838-73.423 0.0904 | 2.722 0.574-48.690 0.2501 |
| Tumor budding                 | High vs Low 2.291 1.170-4.285 0.0169 | 1.667 0.825-3.237 0.1497 | 2.090 0.847-4.752 0.1052 |
| Desmoplastic reaction         | Immature vs Intermediate 1.520 0.712-3.204 0.2736 |                          | 1.227 0.451-3.118 0.6754 |
| Immature vs Mature            | 2.322 1.076-4.976 0.0324 | 0.993 0.415-2.340 0.9867 | 3.293 1.092-10.245 0.0348 | 1.596 0.493-5.305 0.4312 |
| Intermediate vs Mature        | 1.527 0.733-3.202 0.2558 |                          | 2.684 1.021-7.7933 0.0452 | 1.895 0.696-5.686 0.2143 |
| α-SMA                         | Positive vs Negative 1.423 0.437-8.736 0.6078 |                          | 1.580 0.333-28.264 0.6303 |
| CD10                          | Positive vs Negative 0.657 0.267-1.391 0.2883 |                          | 0.704 0.295-1.941 0.4698 |
| Podoplanin                    | Positive vs Negative 0.752 0.399-1.496 0.4020 |                          | 0.564 0.251-1.343 0.1872 |
| FSP1                          | Positive vs Negative 0.355 0.108-2.185 0.2181 |                          | 0.296 0.061-5.139 0.3172 |
| FAP                           | Positive vs Negative 0.819 0.425-1.520 0.5323 |                          | 4.045 0.853-72.358 0.0866 |
| Tenascin-C                    | Positive vs Negative 5.025 2.164-14.621 0.0001 | 3.973 1.656-11.795 0.0012 | 4.527 1.559-19.172 0.0036 | 3.188 1.038-13.882 0.0421 |
| PDGFR-β                       | Positive vs Negative 1.290 0.685-2.566 0.4395 |                          | 1.416 0.611-3.661 0.4288 |
| ZEB1                          | Positive vs Negative 0.683 0.248-2.825 0.5463 |                          | 0.562 0.166-3.510 0.4713 |
| TWIST1                        | Positive vs Negative 1.067 0.581-1.971 0.8331 |                          | 1.237 0.553-2.818 0.6028 |
| Ki-67                         | Positive vs Negative 1.667 0.885-3.316 0.1157 |                          | 2.952 1.187-8.906 0.0185 | 2.114 0.834-6.465 0.1191 |
| p53                           | Positive vs Negative 1.362 0.730-2.663 0.3378 |                          | 1.255 0.552-3.096 0.5955 |
| MMP7                          | Positive vs Negative 0.651 0.354-1.199 0.1671 |                          | 0.823 0.368-1.875 0.6358 |
| β-catenin                     | Positive vs Negative 2.119 1.143-4.084 0.0169 | 1.502 0.796-2.940 0.2121 | 1.865 0.830-4.440 0.1323 |
| E-cadherin*                   |                          |                          |                          |
HIF1-α

WDA, well-differentiated adenocarcinoma. MDA, moderately differentiated adenocarcinoma. HR, Hazard ratio. 95%CI, 95% confidence interval. *, could not analyze, why all cases were positive expression of the marker.

Figures

Figure 1

Representative features of immunohistochemical staining of biological markers we examined based on expression level (low and high). (A) α-SMA. (B) CD10. (C) podoplanin. (D) FSP1. (E) FAP. (F) tenascin-C. (G) PDGFR-β. (H) ZEB1. (I) TWIST1. (J) Ki-67. (K) p53. (L) MMP7. (M) β-catenin. (N) E-cadherin. (O) HIF1-α.

Figure 2

Hierarchical cluster analysis of colorectal cancer patients with stage II or III disease based on the expression patterns of cancer cells and cancer-associated fibroblast (CAF) proteins in the first cohort. The examined CRCs were subclassified into 3 subgroups.
Figure 3

Marker expression levels. A. Expression level of each marker in the first cohort. (A) α-SMA, (B) CD10, (C) Podoplanin, (D) FSP1, (E) FAP, (F) tenascin-C, (G) PDGFR-β, (H) ZEB1, (I) TWIST, (J) Ki-67, (K) p53, (L) MMP7, (M) β-catenin, (N) E-cadherin and (O) HIF1-α.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SugaiTs supplementary tables.docx
- supplementary figure1..tiff